" />
debunking myths

To Off-Shore or Not to Off-shore – Critical factors impacting this decision for Medical Writing

For webinar on demand, write to us at bd@siroclinpharm.com
In the past few years, the pharmaceutical industry has been subjected to increased regulatory scrutiny which has resulted in an exponential increase in the number of documents required to be submitted to the regulatory agencies. With internal medical writing capacity overwhelmed, outsourcing of medical writing, especially to emerging markets is an option that has been used by many organizations.

However, there are several myths associated with outsourcing of medical writing services to offshore locations in emerging markets. So, how does a pharmaceutical company take the decision to off-shore medical writing? Does it improve productivity? Is quality satisfactory?

In this webinar, we debunk the many myths associated with off-shoring of medical writing to emerging markets.

Learning Objectives

  • Debunking myths about outsourcing/ off-shoring
  • Ensuring quality while off-shoring medical writing
  • Influence pharmas to evaluate the appropriate medical writing agency
  • Allow pharmas to analyze the nuances of medical writing business and plan a successful build
  • Help understand and mitigate the challenges faced offshore for guaranteed success
  • Resourcing models and case studies

Who Should Attend?

  • Medical Writing and Medical Affairs personnel
  • Scientific Publication SMEs and Directors
  • Drug Safety & Risk Management executives
  • Clinical Trial Disclosure specialists
  • Outsourcing & Procurement executives

For futher information please email us at bd@siroclinpharm.com

Speaker Profile

Dr. Vatsal Shah

Global Head - Medical Writing & Pharmacovigilance, SIRO Clinpharm

He brings to board over 17 years of varied experience encompassing all phases of clinical research & all document types for medical writing from academia as well as all perspectives of industry (pharma, CRO & BPO).

His major achievements include establishing departments and leading their expansion plans, operational efficiency and sales growth. This includes SIRO's medical affairs and pharmacovigilance department back in 2001, Reliance's medical affairs and pharmacovigilance department in 2008 and Novartis' first-of-its-kind medical writing unit in India, including document management documentum – CREDI/ webEDI), in 2005.

In his most recent stint with Cognizant, he built and led the presales, sales, transition and operations of medical writing (publication & regulatory writing), pharmacovigilance and document publishing.

As part of the Centre of Excellence, Vatsal has largely concentrated on guiding his teams to achieve operational excellence by competency development through training & certified courses, Black Belt project on quality, and establishing a culture driven by metrics & automation.

To know more about SIRO’s Medical Writing services CLICK HERE